New drug cocktail offers hope for Hard-to-Treat head and neck cancer
NCT ID NCT07354984
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of three drugs (docetaxel, nimotuzumab, and pucotenlimab) in 30 adults with recurrent or metastatic head and neck cancer that has not responded to previous treatments. The goal is to see if this therapy can shrink tumors and improve survival. Participants must be between 18 and 75 years old and in good general health.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug cocktail aims to tackle recurrent head and neck cancer
- New drug combo targets Hard-to-Treat head and neck cancers
- Promising drug cocktail targets Hard-to-Treat head and neck cancer
- New drug combo targets Hard-to-Treat head and neck cancer
- New hope for head and neck cancer: drug combo shows promise after standard treatment fails
- Promising combo therapy for head and neck cancer hits early snag